NASDAQ:TPST
Tempest Therapeutics, Inc.
- Stock
locale
United States
market
STOCKSindustry
Biotechnologywebsite
www.tempesttx.comipo date
Nov 12, 2012
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated recepto...Show More
Earnings
Earnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus